Butyrylthiocholine

Identification

Name
Butyrylthiocholine
Accession Number
DB04250
Description

A sulfur-containing analog of butyrylcholine which is hydrolyzed by butyrylcholinesterase to butyrate and thiocholine. It is used as a reagent in the determination of butyrylcholinesterase activity. [PubChem]

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 190.326
Monoisotopic: 190.126559957
Chemical Formula
C9H20NOS
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UCholinesterase
substrate
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AclidiniumThe serum concentration of Aclidinium can be increased when it is combined with Butyrylthiocholine.
AmbenoniumAmbenonium may increase the neuromuscular blocking activities of Butyrylthiocholine.
AprotininAprotinin may increase the neuromuscular blocking activities of Butyrylthiocholine.
CapsaicinCapsaicin may increase the neuromuscular blocking activities of Butyrylthiocholine.
ChloroprocaineThe serum concentration of Butyrylthiocholine can be increased when it is combined with Chloroprocaine.
ChlorpromazineChlorpromazine may increase the neuromuscular blocking activities of Butyrylthiocholine.
CinchocaineCinchocaine may increase the neuromuscular blocking activities of Butyrylthiocholine.
CisplatinCisplatin may increase the neuromuscular blocking activities of Butyrylthiocholine.
ClevidipineThe serum concentration of Clevidipine can be increased when it is combined with Butyrylthiocholine.
CocaineThe serum concentration of Butyrylthiocholine can be increased when it is combined with Cocaine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as fatty acyl thioesters. These are thioester derivatives of a fatty acid with the general formula RC(=O)SR', where R is the fatty acyl chain.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acyl thioesters
Direct Parent
Fatty acyl thioesters
Alternative Parents
Tetraalkylammonium salts / Thioesters / Carbothioic S-esters / Sulfenyl compounds / Carboxylic acids and derivatives / Organopnictogen compounds / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
show 2 more
Substituents
Aliphatic acyclic compound / Amine / Carbonyl group / Carbothioic s-ester / Carboxylic acid derivative / Fatty acyl thioester / Hydrocarbon derivative / Organic cation / Organic nitrogen compound / Organic oxide
show 11 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
quaternary ammonium ion (CHEBI:41055)

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
AWBGQVBMGBZGLS-UHFFFAOYSA-N
InChI
InChI=1S/C9H20NOS/c1-5-6-9(11)12-8-7-10(2,3)4/h5-8H2,1-4H3/q+1
IUPAC Name
[2-(butanoylsulfanyl)ethyl]trimethylazanium
SMILES
CCCC(=O)SCC[N+](C)(C)C

References

General References
Not Available
PubChem Compound
20689
PubChem Substance
46508351
ChemSpider
19484
BindingDB
8978
ChEBI
41055
ChEMBL
CHEMBL139908
ZINC
ZINC000001592591
PDBe Ligand
BCH
PDB Entries
1p0p / 2ha7

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00606 mg/mLALOGPS
logP-2.4ALOGPS
logP-2.6ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)-6.1ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area17.07 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity67.07 m3·mol-1ChemAxon
Polarizability22.74 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.8059
Blood Brain Barrier+0.9596
Caco-2 permeable+0.6708
P-glycoprotein substrateSubstrate0.5159
P-glycoprotein inhibitor INon-inhibitor0.9671
P-glycoprotein inhibitor IINon-inhibitor0.9386
Renal organic cation transporterNon-inhibitor0.6941
CYP450 2C9 substrateNon-substrate0.8126
CYP450 2D6 substrateNon-substrate0.7198
CYP450 3A4 substrateNon-substrate0.5202
CYP450 1A2 substrateNon-inhibitor0.7783
CYP450 2C9 inhibitorNon-inhibitor0.9141
CYP450 2D6 inhibitorNon-inhibitor0.8961
CYP450 2C19 inhibitorNon-inhibitor0.8986
CYP450 3A4 inhibitorNon-inhibitor0.9775
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9677
Ames testNon AMES toxic0.9455
CarcinogenicityCarcinogens 0.703
BiodegradationNot ready biodegradable0.5133
Rat acute toxicity2.7068 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8475
hERG inhibition (predictor II)Non-inhibitor0.6131
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Bourne Y, Radic Z, Sulzenbacher G, Kim E, Taylor P, Marchot P: Substrate and product trafficking through the active center gorge of acetylcholinesterase analyzed by crystallography and equilibrium binding. J Biol Chem. 2006 Sep 29;281(39):29256-67. doi: 10.1074/jbc.M603018200. Epub 2006 Jul 12. [PubMed:16837465]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Bourne Y, Radic Z, Sulzenbacher G, Kim E, Taylor P, Marchot P: Substrate and product trafficking through the active center gorge of acetylcholinesterase analyzed by crystallography and equilibrium binding. J Biol Chem. 2006 Sep 29;281(39):29256-67. doi: 10.1074/jbc.M603018200. Epub 2006 Jul 12. [PubMed:16837465]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates